NeuraSignal

Executive Summary

NeuraSignal is a Houston-based digital health company developing an AI-powered robotic transcranial Doppler (TCD) ultrasound system, the NG2 Intelligent Ultrasound, for non-invasive cerebral blood flow monitoring. The platform addresses the critical need for standardized, objective brain hemodynamic assessments in stroke diagnosis and management, particularly for right-to-left shunt detection (e.g., PFO) and emboli monitoring. By automating probe positioning and leveraging machine learning for real-time signal analysis, NeuraSignal reduces operator dependency and improves diagnostic consistency. The company is targeting the large and growing stroke diagnostics market, where timely and accurate assessment of cerebral blood flow can significantly impact treatment decisions and patient outcomes. The NG2 system is currently in commercial development, with the company pursuing FDA clearance for stroke-related indications. NeuraSignal's technology has the potential to disrupt the traditional TCD market by making advanced brain monitoring more accessible in emergency and critical care settings. While the company is private and has not disclosed funding, its innovative approach positions it well for partnerships with stroke centers and hospital networks. Key risks include regulatory hurdles and competition from established ultrasound and neuromonitoring players. With the increasing focus on telemedicine and automated diagnostics, NeuraSignal is poised to capture value in the acute stroke care pathway.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for NG2 system for emboli detection and PFO screening70% success
• Q1 2027Publication of pivotal clinical trial results demonstrating non-inferiority to traditional TCD60% success
• Q2 2026Series A funding round led by healthcare-focused venture capital80% success